Latest news with #DELFI
CNBC
07-07-2025
- Business
- CNBC
This energy stock is trading near its lowest valuation on record. How to trade it using options
Energy companies have always held a special place for me because one of the first products I traded when I first entered the business in the mid-1990s was options on the Philadelphia Oil Services Index and its associated constituents. Some of the names in the index have changed since then, but Schlumberger remains the largest. A leading oilfield services company, Schlumberger faces a complex landscape in 2025. Ultimately, its economic fortunes rise and fall with the tide of oil prices. Lately, that tide has been going out. Despite tariff uncertainties, the International Energy Agency sees global oil demand growing modestly by 1.2%, fueled by non-OECD markets such as China and India. SLB's diversified portfolio — spanning drilling, production, and digital solutions — captures this growth, with 60% of revenue coming from international markets that are less exposed to U.S. housing weakness. Its digital transformation, including the DELFI platform, enhances efficiency, boosting margins (Q1 2025 adjusted EBITDA margin: 25.3%, up 120 bps YoY). Strategic partnerships, like the $7.8 billion ADNOC contract, secure long-term revenue in high-margin Middle East markets. Financially, SLB's Q1 2025 results outperformed. Management raised 2025 guidance, projecting 15% revenue growth and EPS of $3.50, implying a forward P/E of 13, which is below that of peers like Halliburton. SLB's $3 billion share buyback and 2.3% dividend yield enhance shareholder value, supported by $1.2 billion in free cash flow. Tariffs (on equipment imports, for example) should be manageable, as SLB's global supply chain and localized production mitigate costs. A potential Federal Reserve rate cut (39 bps priced for 2025) could ease debt costs. Geopolitical tensions (e.g., OPEC+ cuts) create some support for oil prices, which in turn would support upstream investment. Technicals are mostly bullish, with eight of the top 10 best-performing indicators, including the Commodity Channel Index, flashing buy signals. That said, the longer-term trend since mid-2023 has been lower, and the stock has not meaningfully broken above the 150-day moving average since Q4 that year. So, what explains the weakness? Global oil demand growth is slow. Energy transition pressures curbing upstream investment. U.S. shale activity, 20% of SLB's revenue, is stagnating, with rig counts down 5% YoY (Baker Hughes, June 2025) Oil price volatility, along with geopolitical risks such as potential OPEC+ oversupply or a U.S.-China trade escalation, could push oil prices lower. Concerns about the Strait of Hormuz, which caused a brief spike in oil prices, have since been reversed as observers have determined that Iran would only harm itself if it threatened that vital oil shipping lane. Schlumberger will be reporting earnings on July 18. The average of sell-side analyst estimates is for adjusted EPS of 74 cents per share on revenue of $ 8.518 billion, down 11.6% and more than 6%, respectively, from the prior year. That said, valuation multiples are near their lowest levels on record, approaching numbers only seen previously during market crashes like the pandemic and the great financial crisis. I don't usually encourage trying to "catch the falling knife," but the stock has stabilized off the April lows. One way to take advantage of a basing situation, if that's what this is, would be to sell some puts. If the stock continues sideways or rallies one keeps the premium (and can potentially reload). Worst case one would own the stock at a discount, not far above the April lows. Here's the trade: Sell 1 Aug. 15 $35 put DISCLOSURES: None. All opinions expressed by the CNBC Pro contributors are solely their opinions and do not reflect the opinions of CNBC, NBC UNIVERSAL, their parent company or affiliates, and may have been previously disseminated by them on television, radio, internet or another medium. THE ABOVE CONTENT IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY . THIS CONTENT IS PROVIDED FOR INFORMATIONAL PURPOSES ONLY AND DOES NOT CONSITUTE FINANCIAL, INVESTMENT, TAX OR LEGAL ADVICE OR A RECOMMENDATION TO BUY ANY SECURITY OR OTHER FINANCIAL ASSET. THE CONTENT IS GENERAL IN NATURE AND DOES NOT REFLECT ANY INDIVIDUAL'S UNIQUE PERSONAL CIRCUMSTANCES. THE ABOVE CONTENT MIGHT NOT BE SUITABLE FOR YOUR PARTICULAR CIRCUMSTANCES. BEFORE MAKING ANY FINANCIAL DECISIONS, YOU SHOULD STRONGLY CONSIDER SEEKING ADVICE FROM YOUR OWN FINANCIAL OR INVESTMENT ADVISOR. Click here for the full disclaimer.
Yahoo
12-05-2025
- Business
- Yahoo
DELFI Diagnostics CTO Recognized among 2025 Most Influential Women in Bay Area Business
Dr. Amoolya Singh Honored as Exceptional Business Leader by San Francisco Business Times BALTIMORE and PALO ALTO, Calif., May 12, 2025 /PRNewswire/ -- DELFI Diagnostics, Inc., developer of innovative blood-based tests that leverage cell-free DNA (cfDNA) fragmentomics for cancer detection and monitoring, today announced that its Chief Technology Officer, Dr. Amoolya Singh, has been named to the San Francisco Business Times' 2025 Most Influential Women in Bay Area Business list. Dr. Singh, who was previously named to this list in 2021, joined DELFI in December 2024 and has over two decades of experience working at the intersection of biotechnology and computational science. She boasts an impressive track record of developing breakthrough genomic technologies and products. As the CTO of DELFI Diagnostics, she leads the company's strategic technology roadmap to help deliver reliable, affordable, and non-invasive tests that enhance cancer detection and transform how cancer is diagnosed and treated, particularly for high-risk patients in underserved communities. "Amoolya excels at integrating biology and assay with computational science and software, and combines her technical skills with a collaborative approach to leadership that ensures her teams can work together to push the boundaries of science and technology and ultimately, revolutionize healthcare," said Susan Tousi, CEO of DELFI Diagnostics. "We're proud of this recognition and that she's part of our team of experts working to improve the accuracy and accessibility of cancer screening." The San Francisco Business Times' annual Most Influential Women in Bay Area Business list recognizes exceptional business leaders making significant contributions to their companies, industries, and communities. Dr. Singh was selected from nearly 400 nominees. "I'm honored to be listed among these notable leaders in Bay Area business," added Dr. Singh. "I am passionate about people and science, and my focus will always remain on making an impact in my work, while ensuring it serves others. I believe strongly in DELFI's mission, and I am excited to advance its groundbreaking research further and reduce it to practice." DELFI's AI-driven approach enables earlier intervention for high-risk populations and creates new opportunities for treatment monitoring. It is the only demonstrated approach enabling population-scale screening. The clinically validated FirstLook Lung is DELFI's blood test designed to improve early detection of lung cancer, which remains the leading cause of cancer deaths in the United States. DELFI also launched the DELFI-TF Assay and related services to help actively guide critical oncology drug development decisions for pharmaceutical companies. The technology is designed to deliver essential insights at every stage of the metastatic cancer journey, from baseline assessment and response monitoring to resistance detection and continuous insight across all treatment lines. For more information about DELFI and its approach, visit About DELFI Diagnostics DELFI Diagnostics is developing next-generation, blood-based tests that are accurate, accessible, and deliver a new way to help detect cancer. DELFI tests are built to solve the highest-burden population health issues, including in historically underserved demographics, and have the potential to save lives on a global scale. FirstLook Lung, for individuals eligible for lung cancer screening, is our first laboratory-developed screening test and requires a simple blood draw that can be incorporated with routine blood work. The test is based on fragmentomics, the discovery that cancer cells are more chaotic than normal cells and, when they die, leave behind tell-tale patterns and characteristics of cell-free DNA (cfDNA) fragments in the blood. The DELFI platform applies advanced machine-learning technology to whole-genome sequencing data to assess individuals' cfDNA fragments against populations with and without cancer. FirstLook Lung uses these millions of data points to reliably identify individuals who may have cancer detected through low-dose CT, including early-stage disease, with a negative predictive value of 99.8 percent. This test has not been cleared or approved by the FDA. View original content to download multimedia: SOURCE DELFI Diagnostics Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
